sftd
NeuRx DPS RA/4 Respiratory Stimulation System, FDA-Approved
Filed in archive FDA Approvals , Medical Devices , News by Gloria Gamat on June 19, 2008
An implantable electronic device that stimulates the diaphragm and allows certain spinal cord injury patients to breathe for at least four hours a day without a mechanical ventilator - NeuRx DPS RA/4 Respiratory Stimulation System - has been approved by the US FDA.

The_NeuRx_DPS_System.gif



Patients with severe spinal cord injuries who cannot control their diaphragms often need mechanical ventilation to help them breathe. This usually requires a full-time connection to a ventilation machine.

The NeuRx DPS RA/4 uses four electrodes implanted in the muscle of the diaphragm to electronically stimulate contraction; this stimulation allows the patient to inhale.

The FDA approved the distribution of this device under a Humanitarian Device Exemption, an approval process for devices intended to treat or diagnose conditions that affect fewer than 4,000 people per year.


NeuRx DPS RA/4 Respiratory Stimulation System is manufactured by Synapse Biomedical.

Source: FDA News

Permalink: NeuRx DPS RA/4 Respiratory Stimulation System, FDA-Approved
Tags: NeuRx  DPS  RA/4  Respiratory  Stimulation  System  spinal  chord  injury  diaphragm  mechanical  ventilator  he 
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/126740
img Addthis img Ask img Blinklist img del.icio.us img Digg img Fark img Facebook img Google img Lycos img Ma.gnolia Add this page to Mister Wong Mr Wong img Netscape img Netvousz img Newsvine img Reddit img StumbleUpon img Slashdot img Tailrank img Technorati img Wink img Yahoo

Vote for NeuRx DPS RA/4 Respiratory Stimulation System, FDA-Approved:

  • Currently 6.40/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 6.40 out of 5 vote(s) cast.
Subscribe
Share It
RSSrss
See all blog subscribe options
Google google
What is RSS?
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Newsletter

TwitterFollow us on Twitter!